Drugs / NKG2D Chimeric Antigen Receptor NK Cell Injection
NKG2D Chimeric Antigen Receptor NK Cell Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06379451 | Apr 2024 → Dec 2025 | plasma cell myeloma | Changzhou No.2 People's Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NKG2D Chimeric Antigen Receptor NK Cell Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06379451 ↗ |
| Action | Activate | “activating NK cell killing activity through NKG2D-NKG2DL interaction.” NCT06379451 ↗ |
| Modality | Cell therapy | “CAR-NK cells” NCT06379451 ↗ |